Read by QxMD icon Read

Journal of the National Cancer Institute

Michael J Overman, Renata Ferrarotto, Kanwal Raghav, Binsah George, Wei Qiao, Karime K Machado, Leonard B Saltz, Thibault Mazard, J N Vauthey, Paulo M Hoff, Brian Hobbs, Evelyn M Loyer, Scott Kopetz
Background: Oxaliplatin-based chemotherapy can cause hepatic sinusoidal injury (HSI), portal hypertension, and splenic sequestration of platelets. Evidence suggests that bevacizumab may protect against HSI. Methods: Two cohorts of metastatic colorectal cancer (CRC) were analyzed: a nonrandomized exploratory cohort of 184 patients treated at a single institution from 2003 to 2010 and a confirmatory cohort of 200 patients from a multi-institutional randomized trial (NO16966)...
January 15, 2018: Journal of the National Cancer Institute
Ting-Yuan David Cheng, Amy K Darke, Mary W Redman, Gary R Zirpoli, Warren Davis, Rochelle Payne Ondracek, Wiam Bshara, Angela R Omilian, Robert Kratzke, Mary E Reid, Julian R Molina, Jill M Kolesar, Yuhchyau Chen, Robert M MacRae, James Moon, Philip Mack, David R Gandara, Karen Kelly, Regina M Santella, Kathy S Albain, Christine B Ambrosone
Background: To what extent steroid hormones contribute to lung cancer in male and female never smokers and smokers is unclear. We examined expression of hormone receptors in lung tumors by sex and smoking. Methods: Patients with primary non-small cell lung cancer were recruited into an Intergroup study in the United States and Canada, led by SWOG (S0424). Tumors from 813 cases (450 women and 363 men) were assayed using immunohistochemistry for estrogen receptor (ER)-α, ER-β, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)...
January 13, 2018: Journal of the National Cancer Institute
Qianxing Mo, Fotis Nikolos, Fengju Chen, Zoe Tramel, Yu-Cheng Lee, Kazukuni Hayashi, Jing Xiao, Jianjun Shen, Keith Syson Chan
Background: Muscle-invasive bladder cancers (MIBCs) cause approximately 150 000 deaths per year worldwide. Survival for MIBC patients is heterogeneous, with no clinically validated molecular markers that predict clinical outcome. Non-MIBCs (NMIBCs) generally have favorable outcome; however, a portion progress to MIBC. Hence, development of a prognostic tool that can guide decision-making is crucial for improving clinical management of bladder urothelial carcinomas. Methods: Tumor grade is defined by pathologic evaluation of tumor cell differentiation, and it often associates with clinical outcome...
January 12, 2018: Journal of the National Cancer Institute
David J McConkey, Woonyoung Choi
No abstract text is available yet for this article.
January 12, 2018: Journal of the National Cancer Institute
Dominique S Michaud, Jiayun Lu, Alexandra Y Peacock-Villada, John R Barber, Corinne E Joshu, Anna E Prizment, James D Beck, Steven Offenbacher, Elizabeth A Platz
Background: While evidence is increasingly consistent with a positive association between periodontitis and cancer risk, most studies have relied on self-reported periodontitis. In this study, we prospectively evaluated the association of periodontal disease severity with cancer risk in black and white older adults in a cohort study that included a dental examination. Methods: Included were 7466 participants in the Atherosclerosis Risk in Communities study cohort who at visit 4 (1996-1998) reported being edentulous or underwent the dental examination...
January 12, 2018: Journal of the National Cancer Institute
Turkan Ozturk Topcu, Katarzyna J Jerzak, Ellen Warner
No abstract text is available yet for this article.
January 10, 2018: Journal of the National Cancer Institute
Matteo Lambertini, Lieveke Ameye, Marianne Paesmans, Fedro A Peccatori, Hatem A Azim
No abstract text is available yet for this article.
January 10, 2018: Journal of the National Cancer Institute
Jessica A Lasky-Su, Oana A Zeleznik, A Heather Eliassen
No abstract text is available yet for this article.
January 9, 2018: Journal of the National Cancer Institute
Steven C Moore, Mary C Playdon, Joshua N Sampson, Robert N Hoover, Britton Trabert, Charles E Matthews, Regina G Ziegler
Background: Elevated body mass index (BMI) is associated with increased risk of postmenopausal breast cancer. The underlying mechanisms, however, remain elusive. Methods: In a nested case-control study of 621 postmenopausal breast cancer case participants and 621 matched control participants, we measured 617 metabolites in prediagnostic serum. We calculated partial Pearson correlations between metabolites and BMI, and then evaluated BMI-associated metabolites (Bonferroni-corrected α level for 617 statistical tests = P < 8...
January 9, 2018: Journal of the National Cancer Institute
Willemijne A M E Schrijver, Karijn P M Suijkerbuijk, Carla H van Gils, Elsken van der Wall, Cathy B Moelans, Paul J van Diest
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated. Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases...
January 5, 2018: Journal of the National Cancer Institute
Kala Visvanathan, Tian-Li Wang, Ie-Ming Shih
No abstract text is available yet for this article.
December 21, 2017: Journal of the National Cancer Institute
Britton Trabert, Sally B Coburn, Andrea Mariani, Hannah P Yang, Philip S Rosenberg, Gretchen L Gierach, Nicolas Wentzensen, Kathy A Cronin, Mark E Sherman
Background: Recognition that serous tubal intraepithelial carcinoma (STIC) may represent the first manifestation of many high-grade cancers that were once considered ovarian primary tumors has led to changes in diagnostic practices that could dramatically increase the reporting of tubal carcinomas in US population-based cancer registries. Further, increased detection of early-stage tubal carcinomas through increased recognition coupled with meticulous pathology processing protocols raises important unanswered questions about the clinical behavior of such lesions, which can only be answered using large data sets...
December 21, 2017: Journal of the National Cancer Institute
Eric C Leas, John P Pierce, Tarik Benmarhnia, Martha M White, Madison L Noble, Dennis R Trinidad, David R Strong
Background: Despite strong efficacy in randomized trials, the population effectiveness of pharmaceutical aids in long-term smoking cessation is lacking, possibly because of confounding (factors that are associated with both pharmaceutical aid use and difficulty quitting). Matching techniques in longitudinal studies can remove this confounding bias. Methods: Using the nationally representative Tobacco Use Supplement to the Current Population Survey (TUS-CPS), we assessed the effectiveness of medications to aid quitting among baseline adult smokers who attempted to quit prior to one year of follow-up in two longitudinal studies: 2002-2003 and 2010-2011...
December 21, 2017: Journal of the National Cancer Institute
Hilary A Tindle, Robert A Greevy
No abstract text is available yet for this article.
December 21, 2017: Journal of the National Cancer Institute
L Lee Dupuis, Donna L Johnston, Christina Baggott, Shannon Hyslop, Deborah Tomlinson, Paul Gibson, Andrea Orsey, David Dix, Vicky Price, Magimairajan Vanan, Carol Portwine, Susan Kuczynski, Brenda Spiegler, George A Tomlinson, Lillian Sung
Background: The objective was to evaluate the reliability and validity of the self-report Symptom Screening in Pediatrics Tool (SSPedi) from the perspective of children with cancer and pediatric hematopoietic stem cell transplant (HSCT) recipients. Methods: In this multicenter study, respondents were children age eight to 18 years who had cancer or had received HSCT, and their parents. Two different child respondent populations were targeted. More symptomatic respondents were receiving active treatment for cancer, admitted to the hospital, and expected to be in the hospital three days later...
December 20, 2017: Journal of the National Cancer Institute
Katrin M Sjoquist, Lindsay A Renfro, R John Simes, Niall C Tebbutt, Stephen Clarke, Matthew T Seymour, Richard Adams, Timothy S Maughan, Leonard Saltz, Richard M Goldberg, Hans-Joachim Schmoll, Eric Van Cutsem, Jean-Yves Douillard, Paulo M Hoff, Joel Randolph Hecht, Christophe Tournigand, Cornelis J A Punt, Miriam Koopman, Herbert Hurwitz, Volker Heinemann, Alfredo Falcone, Rainer Porschen, Charles Fuchs, Eduardo Diaz-Rubio, Enrique Aranda, Carsten Bokemeyer, Ioannis Souglakos, Fairooz F Kabbinavar, Benoist Chibaudel, Jeffrey P Meyers, Daniel J Sargent, Aimery de Gramont, John R Zalcberg
Background: Estimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical trials. We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database. Methods: Data from 22 674 patients in 26 randomized phase III clinical trials since 1997 were used to construct and validate Cox models, stratified by treatment arm within each study...
December 18, 2017: Journal of the National Cancer Institute
Leah Shepherd, Lene Ryom, Matthew Law, Camilla Ingrid Hatleberg, Stephane de Wit, Antonella d'Arminio Monforte, Manuel Battegay, Andrew Phillips, Fabrice Bonnet, Peter Reiss, Christian Pradier, Andrew Grulich, Caroline Sabin, Jens Lundgren, Amanda Mocroft
Background: Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) are increased in populations with immune dysfunction, including people living with HIV; however, there is little evidence for to what degree immunological and virological factors differently affect NHL and HL risk. Methods: Data from the Data Collection on Adverse events of Anti-HIV Drugs Study cohort were analyzed to identify independent risk factors for NHL and HL using hazard ratios (HRs), focusing on current and cumulative area under the curve (AUC) measures of immunological and virological status...
December 18, 2017: Journal of the National Cancer Institute
Jodi A McKenzie, Rina M Mbofung, Shruti Malu, Min Zhang, Emily Ashkin, Seram Devi, Leila Williams, Trang Tieu, Weiyi Peng, Sunila Pradeep, Chunyu Xu, Soraya Zorro Manrique, Chengwen Liu, Lu Huang, Yuan Chen, Marie-Andree Forget, Cara Haymaker, Chantale Bernatchez, Nikunj Satani, Florian Muller, Jason Roszik, Ashish Kalra, Timothy Heffernan, Anil Sood, Jianhua Hu, Rodabe Amaria, R Eric Davis, Patrick Hwu
Background: Immunotherapy has increasingly become a staple in cancer treatment. However, substantial limitations in the durability of response highlight the need for more rational therapeutic combinations. The aim of this study is to investigate how to make tumor cells more sensitive to T-cell-based cancer immunotherapy. Methods: Two pairs of melanoma patient-derived tumor cell lines and their autologous tumor-infiltrating lymphocytes were utilized in a high-throughput screen of 850 compounds to identify bioactive agents that could be used in combinatorial strategies to improve T-cell-mediated killing of tumor cells...
December 18, 2017: Journal of the National Cancer Institute
Richard L Schilsky, Lowell E Schnipper
No abstract text is available yet for this article.
December 13, 2017: Journal of the National Cancer Institute
Ariadna Tibau, Consolación Molto, Alberto Ocana, Arnoud J Templeton, Luis P Del Carpio, Joseph C Del Paggio, Agustí Barnadas, Christopher M Booth, Eitan Amir
Background: It is uncertain whether drugs approved by the US Food and Drug Administration (FDA) have clinically meaningful benefit as determined by validated scales such as the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Methods: We searched the Drugs@FDA website for applications of anticancer drugs from January 2006 to December 2016. Study characteristics, outcomes, and regulatory pathways were collected from drug labels and reports of registration trials...
December 13, 2017: Journal of the National Cancer Institute
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"